A legal challenge has been brought seeking to halt a clinical trial of puberty blockers for children with gender dysphoria until a court has ruled on the underlying dispute. Campaigners or claimants argue that allowing the trial to proceed before the judicial review is resolved could cause irreversible harm, making the case a significant test of how contested medical research on children is regulated while litigation is ongoing.

The full detail of the arguments put before the court, including who brought the challenge and which body is running the trial, was not available in the source material provided. The case adds to the wider, long-running debate in the UK over the use of puberty blockers in the treatment of young people experiencing gender dysphoria, an area that has already prompted regulatory reviews and restrictions on clinical prescribing.